Targeting mast cell as a neuroprotective strategy

Brain Inj. 2019;33(6):723-733. doi: 10.1080/02699052.2018.1556807. Epub 2018 Dec 17.

Abstract

Background: Mast cells (MCs) are perivascularly located immune cells of haematopoietic origin. Emerging evidences suggest that the activation of MCs play important roles in the pathogenesis of blood brain barrier disruption, neuroinflammation, and neurodegeneration. Objectives: In this review, we aimed to discuss the detrimental effects of MCs in response to various types of brain injury, as well as the therapeutic potential and neuroprotective effects of targeting the activation and degranulation of MCs, particularly in the management of the acute phase. Methods: An extensive online literature search was conducted through Pubmed/Central on March 2018. Then, we comprehensively summarized the effects of the activation of brain MCs in acute brain injury along with current pharmacological strategies targeting at the activation of MCs. Results: The review of the current literature indicated that the activation and degranulation of brain MCs significantly contribute to the acute pathological process following different types of brain injury including focal and global cerebral ischaemia, intracerebral haemorrhage, subarachnoid haemorrhage, and traumatic brain injury. Conclusions: Brain MCs significantly contribute to the acute pathological processes following brain injury. In that regard, targeting brain MCs may provide a novel strategy for neuroprotection.

Keywords: Mast cell; brain; neuroinflammation; neuroprotection; stroke; trauma; hypoxia.

Publication types

  • Review

MeSH terms

  • Blood-Brain Barrier / physiopathology
  • Brain Injuries / physiopathology
  • Brain Injuries / therapy*
  • Brain Ischemia / physiopathology
  • Brain Ischemia / therapy*
  • Cerebral Hemorrhage / physiopathology
  • Cerebral Hemorrhage / therapy*
  • Humans
  • Mast Cells / pathology*
  • Neuroprotection*